跳转至内容
Merck
CN

59586-U

Discovery® Cyano (5 µm) HPLC Columns

L × I.D. 2 cm × 4 mm Supelguard Guard Cartridge, pkg of 2 ea, Guard Cartridge holder required for use

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
2 cm × 4 mm
Particle size:
5 μm
Matrix active group:
cyano phase
Pore size:
180 Å
Matrix:
fully porous particle
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Discovery® 氰基 Supelguard 保护柱芯, 5 μm particle size, L × I.D. 2 cm × 4 mm

separation technique

reversed phase, hydrophilic interaction (HILIC), normal phase

material

stainless steel column

agency

suitable for USP L10

description

Supelguard Cartridge

product line

Discovery®

feature

endcapped

packaging

pkg of 2 ea

technique(s)

HPLC: suitable

L × I.D.

2 cm × 4 mm

surface area

200 m2/g

matrix

fully porous particle

matrix active group

cyano phase

particle size

5 μm

pore size

180 Å

operating pH

2-8

application(s)

food and beverages

Quality Level

正在寻找类似产品? 访问 产品对比指南

Packaging

适用于 4.0mm 内径和 4.6mm 内径的分析柱。

Other Notes

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

E F Nemeth et al.
The Journal of pharmacology and experimental therapeutics, 299(1), 323-331 (2001-09-19)
Despite the discovery of many ions and molecules that activate the Ca2+ receptor, there are no known ligands that block this receptor. Reported here are the pharmacodynamic properties of a small molecule, NPS 2143, which acts as an antagonist at
Graciela B Arhancet et al.
Journal of medicinal chemistry, 53(16), 5970-5978 (2010-08-03)
A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships
Aaron D Milstein et al.
Trends in pharmacological sciences, 29(7), 333-339 (2008-06-03)
Presynaptic glutamate release elicits brief waves of membrane depolarization in neurons by activating AMPA receptors. Depending on its precise size and shape, current through AMPA receptors gates downstream processes like NMDA receptor activation and action potential generation. Over a decade
Srdan Verstovsek et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(3), 788-796 (2008-02-05)
The discovery of an activating somatic mutation in codon 617 of the gene encoding the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has opened new avenues for the development of targeted therapies for these malignancies. However, no
K Umekawa et al.
Japanese journal of pharmacology, 84(1), 7-15 (2000-10-24)
We describe the pharmacological characteristics of SM-19712 (4-chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl] benzenesulfonamide, monosodium salt). SM-19712 inhibited endothelin converting enzyme (ECE) solubilized from rat lung microsomes with an IC50 value of 42 nM and, at 10 - 100 microM, had no effect on other

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持